small molecule

BYQLOVI

CLOBETASOL PROPIONATE

Loss of exclusivityMay 2036latest FDA-listed patent expiry

CompanyHARROW EYE LLC

Drug detail

Brand name	BYQLOVI
Active ingredient	CLOBETASOL PROPIONATE
Strength	0.05%
Dosage form	SUSPENSION/DROPS
Route	OPHTHALMIC
Modality	Small molecule
FDA approval	March 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
11376262	May 2036	product
10588913	May 2036	product

Regulatory exclusivity

Code	Expires
NP	March 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from HARROW EYE LLC